2017年 6月 5日
EMERGO SUMMARY OF KEY POINTS:
US Food and Drug Administration medical device regulators have extended Unique Device Identification (UDI) labeling and related compliance deadlines for lower-risk devices to late 2022 in order to fully standardize and optimize UDI data already collected on high-risk devices.
According to a notice to Class I and unclassified device registrants, UDI requirements already in force for many Class II and Class III devices have yielded 1.4 million records submitted to the FDA’s Global Unique Device Identification Database (GUDID) as of May 1, 2017. However, UDI implementation for higher-risk devices has also created tricky technical and policy challenges for both FDA regulators and registrants. Extending UDI labeling timelines for low-risk devices will allow the agency to address and remedy these challenges before even more data is submitted to GUDID.
The FDA plans to issue new guidance covering enforcement discretion for low-risk medical device UDI labeling, GUDID submission, standard date formatting and direct mark obligations.
Class I and unclassified devices will have to meet UDI labeling, GUDID data submission and standard date formatting rules by September 24, 2020. Direct mark requirements under 21 CFR Part 901.45 will have to be met by September 24, 2022 for these low-risk devices.
The new deadlines do not apply to Class I or unclassified devices that are implantable, life-supporting or life-sustaining.